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ABSTRACT  
 
Examining altered neural activation in patients with patellar tendinopathy: a preliminary study 
 
Davi SM, Lepley LK, Lepley AS, Denegar CR, Aerni G, DiStefano LJ: Human Performance 
Laboratory, Department of Kinesiology, University of Connecticut, Storrs, CT. 
 
 
CONTEXT: Patellar tendinopathy (PT) is a common injury that can affect 15-45% of all 
athletes, with nearly 50% of these athletes reporting no longer being able participate in sport due 
to the severity of the injury.  One of the consequences of PT leading to physical inactivity is 
muscular weakness, particularly in the quadriceps, which may be attributed to arthrogenic 
muscle inhibition (AMI). OBJECTIVE: To examine the extent of quadriceps AMI in 
individuals suffering from PT and secondly, to compare subjective reports of pain and 
dysfunction with objective measurements of PT diagnosis.  DESIGN: Case-control.  SETTING: 
Laboratory PARTICIPANTS: Six participants with diagnosed PT (<80 on Victorian Institute of 
Sport Assessment - Patella (VISA-p) and six healthy participants (VISA-p>80) matched to the 
PT group based on age, mass, height, and gender.  INTERVENTION: Each participant 
completed one test session, which included patient-oriented outcome questionnaires, diagnostic 
ultrasound (US), Hoffman’s Reflex (H-Reflex), superimposed burst to assess central activation 
ratio (CAR), and a standardized jump landing test. Neuromuscular control during the jump 
landing was evaluated using the Landing Error Scoring System (LESS) and electromyography 
(EMG) of the vastus medialis and lateralis.   MAIN OUTCOME MEASURES:  H:M ratio, 
CAR, LESS score, percent maximum muscle activation during CAR, and percent stance muscle 
activation during the pre-loading and loading phases of jump landing were assessed between 
groups using independent-t tests (α<0.05). RESULTS:  With respect to CAR, the PT group 
(95.13%±3.46) compared to the healthy group (98.54%±0.60) exhibited a significant loss of 
 vi 
volitional muscle activation (P=.04).  There were no differences between groups for H:M, LESS 
score, or muscle activity (P>0.05).  The PT group was then divided into two sub-groups: 
Subjective (participants that were diagnosed with PT via subjective reports alone)(n=4) and 
Objective (participants that were diagnosed via subjective reports and US)(n=2).  The Objective 
group demonstrated lower CAR, H-Reflex, muscle activity, and a higher LESS score than both 
the Subjective PT group and the healthy group. CONCLUSION:  This study was the first to 
demonstrate deficits in the PT population using measures of peripheral sources of AMI.  Further 
research needs to be conducted on the extent of these deficits and whether AMI induced from PT 
is associated with an increased risk of lower extremity injury. 
Key Words: neuromuscular dysfunction, cortical alterations, peripheral inhibition 
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Chapter I: Review of Literature 
Patellar Tendinopathy  
 
Knee injuries represent 15.2% of all high school injuries and can cause time losses for 
athletes ranging from a few days to being career ending. 1 These injuries can include damage to 
bone, ligament, cartilage, or tendon. Knee injuries are common in lower extremity sports with 
patellar tendinopathy (PT) being one of the most prevalent. 1 While some knee injuries are more 
severe their incidence rates are low compared to a knee injury like patellar tendinopathy, which 
can affect up to 50% of athletes in at the elite volleyball level. 2 Patellar tendinopathy can have 
long-term effects on the ability for athletes to continue with participation in sport. 3,4 
Etiology and Prevalence 
 
PT is very common and can occur in 15-45% of all athletes. 1,5-7  The prevalence of PT in 
elite male volleyball players has been reported to be 45%. 2 PT does not only affect volleyball 
athletes as prevalence in basketball can approach 30%. 6 The prevalence of PT can vary from 
14.4% to 2.5% in non-elite athletes, with males being almost twice as likely than females to have 
the condition. 5,7 Since PT is common in jumping sports at all levels of athletic participation, it is 
important for clinicians to have an understanding of PT etiology. 
The first step in understanding why PT so commonly affects jumping athletes is to 
recognize what PT is and the role of the patellar tendon during activity. Tendinopathy is a 
painful, chronic; overuse injury that is associated with degeneration and disorganization with no 
evidence of inflammation within the tendon. 5,6 There are two main classifications of patellar 
tendon injury; the first is inflammatory enthestis, which is described as inflammation at the site 
where tendon intersects with bone and the second is tendinopathy. 8 Patellar tendinopathy 
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typically presents as pain at the deep proximal portion of the tendon just inferior to the patella 
that may or may not be accompanied by edema. 9 Patients may also present with pain during 
knee extension exercises like squatting and jumping.  Not only can PT produce pain but it has 
been demonstrated to cause concentric quadriceps weakness in female fencers. 10 The main 
purpose of tendon is to transfer force from a muscle to a bone thereby causing joint movement. 6 
Other functions of tendon include energy storage and release in addition to protection of the 
muscle from injury. 6   The patellar tendon must transmit a high volume of force form the 
quadriceps to the tibia in a jumping sport.  
Although the etiology of PT still is not completely understood, a few possible 
explanations for this pathology have been suggested by the literature.  PT is very common in 
sports that include repetitive jumping and landing like basketball and volleyball. 5  Since tendon 
tissue transfers force between muscle and bone, the PT is responsible for absorbing high loads 
and converting this energy to mechanical work that can be utilized during dynamic activities, 
such as jumping.  Given the unique role of the tendon during high-loading activities, a high 
volume of repetitive jumping is a risk factor. 6,9,11-15  Some other possible causes of PT include a 
stiff landing technique, high jump performance, large waist girth, male gender, and high training 
volume. 5 Each of these factors point towards tendinopathy developing when  greater strain is 
present.  Jumping higher and having a large waist girth are two traits most often attributed to 
males and may play a role in the high gender incidence rates. 5  The premise behind these two 
ideas are that landing from a higher height and increased weight will cause more eccentric strain 
during landing.  Having a stiff landing technique is believed to cause increased tendon strain 
because less energy is absorbed through supportive musculature that utilizes a limited range of 
motion, thus transferring more force to the tendon. 5 A new perspective on PT in volleyball may 
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come in the form of genetics, where researchers have found that volleyball players who are 
carriers of the BMP4 and FGF3 genes may be predisposed to developing PT. 2 
The prognosis for untreated PT is poor.  Gisslen et al. 16 showed through a three-year 
observation that patellar tendon condition did not change if training intensity remained the same.  
The study followed 22 high school volleyball players, 11 males and 11 females, through three 
years of school. Each player had both of his or her patellar tendons examined by ultrasound 
(US), and power doppler (PD  For participants who had clinically and sonographically diagnosed 
PT,symptoms remain as long as intense training or competition was present.  The results of this 
study show that without rest PT will be a persistent problem for the jumping athlete. 
In another study that included a measurement for the duration of PT, van der Worp et al. 
17 found that the median length of time a patient suffered from PT was 24 months, however 
duration of symptoms ranged from 1-219 months.  Participants in the study were invited via 
email to fill out an online questionnaire regarding their demographics, current knee injury status, 
sport participation, and occupation.  PT was assessed using the VISA-P.  Men were twice as 
likely to have PT, and those with a physically demanding job in addition to playing sports 
regularly were at greater risk for developing PT.  When untreated PT lasted an average of 24 
months.  Both of these studies demonstrate that untreated PT does not resolve without treatment 
and a decrease in sport or work intensity.  For the clinician, these studies help to outline why PT 
should be taken seriously, especially in males that participate in sport at a high intensity.   
Bisseling et al. 18 further illustrated how landing mechanics can both influence and be 
influenced by PT.  This study assigned 89 male participants into one of three experimental 
groups; 1) a control group with no previous or current PT, 2) a group with a history of PT but no 
current symptoms, and 3) a group that had PT at the time of the trials.  Participants were asked to 
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step off of boxes that were 30cm, 50cm, and 70cm high five times per box height landing one 
foot on a force plate.  The results of the study showed that the group with recent PT tended to 
avoid patellar tendon loading during landing through lowering the velocity and rate of range of 
motion chance of the ankle and knee, while participants with a history of PT tended to land much 
more stiffly than their counterparts.  These data not only suggest that PT can influence the 
alteration of landing mechanics in the short term but that a stiff landing could either be a 
potential cause of PT or a long term side effect of the disorder. 
Signs and Symptoms  
 
The signs and symptoms of PT are considerably better recognized and understood than 
the etiology.  One of the more common symptoms is pain over the proximal tendon during 
loading activities like jumping and squatting. 6 A second indicator is pain on palpation of the 
proximal tendon as it attaches to the inferior patella. 19 Although not as easy to assess clinically, a 
study of patients with PT by Souza et al. 20 found that they display greater hip extensor activation 
and decreased knee extensor activation when compared to asymptomatic controls during a 
hopping task. The experiment compared seven men with history of PT to an equal control group 
without history of PT.  All participants were evaluated for their kinematics and kinetics and 
asked to hop in place for 20 successful hops on a force plate.  Even though the PT group did not 
report painful hopping, they demonstrated a higher ratio of hip joint to knee joint effort than did 
the control group.  This study suggests that those suffering from PT will attempt to reduce knee 
joint loading by using hip extensors to absorb landing forces, which shifts loading from the knee 
to the hip. This shift in loading could possibly be due to a weakness, neuromuscular dysfunction 
of the quadriceps muscle, or as a conscious effort to decrease pain.   
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Signs and symptoms are important when making the determination of whether a patient is 
suffering from PT, however the use of imaging devices is necessary in determining the extent of 
tendon degeneration, disorganization, and vascularization.  Magnetic resonance imaging (MRI), 
ultrasound (US), and power doppler (PD) are all imaging tools used in the diagnosis of PT. 6 All 
three instruments are non-invasive but US is the most widely used imaging for PT. US can be 
used to show tendon thickness, structural changes, and neovascularization. 21 In addition, US has 
a higher spatial resolution than MRI, resulting in a more detailed picture from a portable and 
affordable unit. 21 Finally, although US has a similar specificity to MRI (.82) US has a higher 
sensitivity (.87) than MRI (.57). 8  However, the US is not perfect and one of its biggest 
drawbacks is that sonographic tendon abnormalities often appear in the absence of clinical 
symptoms of PT, 22,23 as 10%-18% of tendons that are abnormal on US never become painful. 22  
Some common abnormalities detected via US are tendon thickening, hypoechoicity of the 
tendon, increased collagen bundle disorganization at the proximal tendon, and greater cross 
sectional area. 22,24,25 While US is useful for visualizing structural abnormalities, both power and 
color doppler are useful in determining vascularity within a tendon and have been able to show 
an association between pain during activity and the amount of vascularization in the tendon. 16 
This association is most likely due to an increase in pain causing chemotaxic factors being 
carried to the injured area.  One drawback of doppler is that only high flow rates, like those 
sometimes present in PT, can be detected. 16 The MRI is the least used of the three because of 
high costs and inability for differentiation between inflammation and degeneration in the 
tendon.24 
The Victorian Institute of Sport Assessment Scale – Patella (VISA-P) is a patient 
reported outcomes questionnaire designed for individuals suffering from PT and is the most 
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widely used assessment for PT. 26 The form consists of eight items that are split into two 
sections.  The first section consists of six parts that look to identify pain levels during activities 
of daily living and functional tests, while the second section has two parts that target the patient’s 
sport participation level. 26 The questionnaire is scored on a scale of 0-100 with 100 being a 
patient that exhibits no signs or symptoms of PT and zero being the bottom of the scale, which is 
the equivalent of total disability.  A recent study 26 has shown that this scale is able to detect and 
represent changes in the patient’s condition.  What this means for the clinician is that he or she 
will have an accurate idea of how their patient is or is not responding to treatment.  The VISA-P 
has also been shown to be accurate in both the online and written formats. It should be noted that 
the questionnaire was not designed to be used in research with control subjects that are not 
suffering from PT, and using the questionnaire in such a way could alter its results. 27   
Arthrogenic Muscle Inhibition 
 
Arthrogenic muscle inhibition (AMI) is often referred to as an ongoing reflex response to 
joint injury that affects the periarticular musculature. 28,29 AMI is hypothesized to be the body’s 
mechanism to protect the injured joint and prevent further painful stimuli. 30 AMI is caused by a 
variety of peripheral and central mechanisms that result in either the loss of the ability to 
volitionally activate alpha motor neurons or a decrease in the alpha motor neuron’s firing rate. 29 
This decreases the ability of periarticular muscle to voluntarily and reflexively contract, which 
can lead to atrophy and poor functional ability. 30 AMI has been detected in the musculature 
surrounding the knee joint following injury, primarily in the quadriceps muscle group. 28,31 
Interestingly it has been reported that anterior knee pain seems to cause a greater magnitude of 
inhibition than does ligamentous injury. 32 
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Peripheral Mechanisms 
The neurologic pathways involved in AMI are complex, which is one of the key reasons 
they are still not completely understood. However, AMI is thought to occur due to peripheral and 
central inhibition or a combination of the two.  In the peripheral pathway either effusion, 
mechanoreceptor damage, and/or pain can cause altered afferent signaling from what would be 
considered normal.  For example, increased afferent activity is what takes place when a joint 
becomes effused. 31 The effusion within the joint space causes a rise in group II articular afferents 
discharge from the joint capsule due to the excessive fluid built up and activated 
mechanoreceptors of the joint capsule.  An example of altered afferent activity would be in the 
case of destroyed mechanoreceptors from the loss of a ligament. 31 Normally, joint 
mechanoreceptors relay information to periarticular musculature, but once they become damaged 
the mechanoreceptors can no longer complete this function.  Both increased and deceased 
afferent signaling can cause presynaptic inhibition of the musculature surrounding the joint.  In 
the patellar tendinopathy population it is most likely that pain at the site of injury would cause 
peripheral AMI due to altered afferent signaling of 1a fibers. 
Central Mechanisms 
Central mechanisms of AMI include pre-synaptic, cortical, and spinal mechanisms.  At 
the pre-synaptic level inhibitory interneurons release GABA, which decreases the ability of the 
neuron to generate an action potential by causing chlorine to change the electrical gradient 
surrounding the neuron. The change in this gradient reduces the amount of calcium entering the 
pre-synaptic terminal and inhibits proper muscular activity. 30  To examine a second mechanism 
of centrally originating AMI, Lepley et al. 33 demonstrated joint injury can cause alterations in 
cortical excitability, which can act to modulate efferent signaling at the alpha motor neuron level.  
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Rio et al 34 conducted similar work in which it was found that chronic PT can influence cortical 
changes also.    
AMI caused by the spinal pathway can originate from gamma motor neuron loop 
dysfunction, reciprocal inhibition of type 1a afferent fibers, non-reciprocal inhibition of type 1b 
fibers, and recurrent inhibition via Renshaw cells 35.  In the gamma loop afferent signals from 
within the injured joint are transmitted to gamma motor neurons (GMN).  These afferent signals 
into the GMN inhibit a signaling process between the GMN and intrafusal fibers within the 
muscle spindle 34.  This alters the shortening reaction of intrafusal fibers within the muscle 
spindles and results in a decreased capacity for muscle contraction. 36 Along with the decrease in 
contractibility, signals from 1a afferent to high threshold motor units are inhibited, which results 
in decreased force output. 30  Inhibition of type 1a afferent fibers is caused by firing of motor 
neurons in the agonist muscle group.  This firing stops the antagonist group from working 
correctly because both the agonist and antagonist groups cannot contract completely 
simultaneously.  Type 1b inhibition is caused by afferent signaling arising from the golgi tendon 
organ to inhibit the agonist muscle group and activate the antagonist group.  Renshaw cells work 
in the spinal cord and cause inhibition of the target muscle group by decreasing the action 
potential that is received by the alpha motor neuron. 30  
Quantifying AMI 
 
Whether to detect the presence of AMI or to quantify the amount of inhibition a muscle is 
experiencing, researchers commonly utilize either the superimposed burst or interpolated twitch 
technique. 37 One of the most often used equations to calculate muscle activation, which can be 
used with either testing method, is the central activation ratio (CAR).  The formula is derived for 
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the patients maximum voluntary isometric contraction (MVIC) by their MVIC plus a stimulated 
force measured in torque. 38  
 
CAR = (MVIC) / (MVIC + stimulated force) 
 
The force of contraction is measured on a dynamometer, which can quantify torque for 
each MVIC. 37 The stimulated force described in the CAR equation is the amount of torque 
caused by a superimposed electrical burst. This process will be described in detail later in this 
paper. CAR is the percentage of complete muscle activation that is occurring.  For example, a 
patient demonstrating a CAR of 1.00 would mean that he or she had complete voluntary muscle 
activation, while a CAR of .8 would signify that the muscle was activated to 80% of its complete 
potential. 39  
CAR measurements are used to determine the amount of voluntary activation possible for 
the specific muscle.  Roberts at al. 37 determined possible confounding variables that can 
influence quadriceps CAR.  The included variables were patient positioning, verbal cueing from 
the clinician, synergistic muscle activation, and antagonist co-contraction.  The purpose of 
measuring CAR is to determine the amount of activation in a specific muscle. It is important that 
only one muscle, or muscle group, be targeted without the use of synergists  Synergistic muscle 
activity includes trunk and arm muscle contractions to stabilize the upper body.  An example of 
antagonist muscles are the hamstring group co-contracting when the quadriceps group is 
activated.  Avoiding hamstring group activation is important because these muscles decrease 
quadriceps activation force.  If the patient is properly positioned and verbally cued on isolating 
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the quadriceps, then synergist and antagonist muscle activation can be avoided. The study went 
on to show that less synergistic muscle involvement can decrease CAR.  
The superimposed burst (SIB) method is used to obtain the CAR to determine the total 
possible torque that all of the motor units for a specific muscle could create in an ideal situation.  
A SIB delivers electrical impulses that are able to increase the total number of motor units being 
recruited, which increases torque beyond a patient’s MVIC. 37.  The SIB can be delivered to a 
muscle in a single, doublet, or train series of pulses. 40 While each method can be used to 
identifyAMI the pulse trains or burst methods have been found to be more sensitive to central 
activation failure (CAF) than the single or double methods. 38 The SIB method has been shown to 
reliably measure central activation of the quadriceps. 37 Even though the method is reliable there 
can be up to a 5% measurement error with the SIB technique. 41 There are different methods 
demonstrated for performing SIB and two have been utilized for the quadriceps.  The 
possibilities include the vastus and rectus configurations and these can be set up with either self-
adhesive or carbon impregnated electrodes.  Both configurations and electrode types have been 
shown to be interchangeable, which demonstrates the versatility of the SIB method. 42  One final 
measure of versatility for the SIB method is that it can be used in the percent activation equation 
with success rates similar to that of CAR.  Researchers have been able to demonstrate that when 
SIB is used with a doublet pulse configuration the percent activation equation correlate well to 
CAR using SIB with a train of pulses. 40 
Although the use of a superimposed burst technique to calculate CAR is effective at 
quantifying AMI, one if the drawbacks is that the method cannot determine where AMI is being 
generated from.  The Hoffmann Reflex (H-Reflex) is a peripheral nerve stimulation technique 
that has been used as an accessory to CAR because of the ability to assess the role that the 
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spinal-reflex loop may play in the development of AMI. 43  An H-Reflex in a peripheral nerve is 
an electrically induced equivalent to the muscular stretch reflex, and looks to account for levels 
of inhibition discussed earlier (presynaptic, postsynaptic).  To record H-Reflex an electrical 
stimulation is delivered to a peripheral nerve, which causes an afferent signal discharge of the 1a 
nerve fiber to the spinal cord, and the efferent “reflex” is detected using electromyography 
(EMG) in muscles innervated by the stimulated nerve. 43  The resulting increase in electrical 
activity within the muscle is represented as a wave on the computer and is considered to the “H-
reflex”.  In subjects with AMI a decrease in peak-to-peak amplitude of the “H-reflex” or an 
increased stimulus voltage needed to elicit comparable peak-to-peak amplitude when compared 
to a healthy or control limb and normalized to muscle response would denote an inability for the 
1a afferent nerve to effectively transmit electrical impulses to the alpha motor neuron, resulting 
in an inability to reflexively contract the muscle.  
 Many confounding variables exist when eliciting the H-Reflex during testing, therefore 
the process must be performed in a controlled environment.  As stated above, presynaptic 
inhibition of afferent sensory signaling can greatly affect the amplitude of the H-reflex.  Changes 
in light, sound, noise, or body position are just a few of disturbances that can cause presynaptic 
inhibition. 43  This inhibition occurs because any external stimuli require afferent signaling to 
reach the spinal cord, as does the H-reflex stimulus.  Any additional stimuli can dilute the 
experimental stimulus for eliciting the H-reflex, which will result in decreased peak-to-peak 
amplitude as detected though EMG assessment. 44   
In addition to the H-reflex, another variable called the M-Wave is also elicited during H-
reflex testing.  As the electrical stimulus is increased, the higher threshold efferent limb of the 
stimulated nerve (i.e. the alpha motor neuron) is directly depolarized.  Once the alpha motor 
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neuron fibers are directly depolarized, the EMG can detect the electrical activity from this event, 
the M-Wave. 43  Since the M-Wave represents direct depolarization of the alpha motor neuron 
there is no influence from the spinal cord.  Thus, the M-Wave represents the maximal capacity of 
the alpha motor neuron excitability, while the H-reflex represents the ability of afferent stimulus 
to evoke efferent spinal cord excitability. These two waves are represented as a ratio of the 
maximum peak-to-peak H-reflex amplitude compared to the maximum peak-to-peak M-Wave 
amplitude, H-reflex Max: M-Wave Max. The comparison of the waves allows researchers to begin 
to make inferences about the source of AMI.  A decreased peak-to-peak H-Wave amplitude with 
no associated decrease in peak-to-peak M-Wave amplitude is believed to show that the spinal 
cord, which is not involved with the M-Wave, is influencing efferent signaling to the muscle 
being tested.  Normalizing H-relfex to muscle response allows the researcher to determine if 
alterations in the H-reflex are also present during muscle response. 
Quadriceps AMI 
 
 Quadriceps AMI is a common consequence of a variety of knee injuries.  In particular, it 
has been estimated that quadriceps strength deficits in patients with ACL ruptures range between 
8%-45%.  Some injuries that have been linked to quadriceps AMI are primary ACL injuries, 
anterior knee pain and osteoarthritis. 29,30,37 Previously discussed in less detail, ACL injuries 
damage mechanoreceptors in the ligament itself, which can cause abnormal afferent information 
to be sent to the CNS and PNS and result in muscle inhibition. 30 This leads to an inability of the 
patient to properly control the quadriceps muscle, potentially leading to biomechanical 
alterations during gait and athletic participation, which could be problematic for active 
individuals. 37    
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 Quadriceps weakness can have major effects for not only the athletic population but also 
the general population that suffers from AMI.  The quadriceps act eccentrically during gait, and a 
weakened muscle with decreased contractility could adversely affect the gait cycle. 32 Quadriceps 
weakness can also cause decreased dynamic joint stability, which could lead to decreased 
functional ability and eventually tibiofemoral osteoarthritis (OA). 31,39   
Palmieri-Smith and Thomas 30 have described some of the changes which take place in 
the knee joint when the ipsilateral quadriceps is experiencing weakness and how this may effect 
articular cartilage.  First, the load placed upon the knee joint increases as quadriceps strength 
decreases.  The authors believe this was due to the quadriceps acting as a shock absorber for the 
knee. When the quadriceps muscles are weak they absorb less force, and more force is 
transmitted to the knee joint and consequently the articular cartilage. Second, altered joint 
kinematics due to muscular inhibition also lead to new stresses to the articular cartilage which 
were not previously present.  This increased stress on articular cartilage is a possible cause for 
OA.  
Manal and Snyder-Mackler 45 looked to identify quadriceps AMI that may be present 
after patellar contusions. In 16 participants with patellar contusion, only 1/3 of patients 
experienced quadriceps muscle AMI with the clinical diagnosis of AMI only being made by 
determining %MVIC. Patient reported outcomes for those diagnosed with AMI did not show any 
deficits in daily function.  The results of this study show that AMI is possible with a relatively 
benign injury, however, without the use of laboratory equipment AMI could easily go unnoticed.  
Once AMI is detected, or thought to be detected, it must be quantified.  Kuenze et al. 41 
examined 22 participants with a history of ACL reconstruction in an attempt to determine return 
to participation criteria for individuals with quadriceps AMI. The study found that 3.00Nm/Kg of 
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normalized quadriceps strength was a good indicator of positive patient reported outcomes in 
regards to knee function, as was CAR symmetry of greater than 99.2 %.  These data provide 
clinicians will a baseline for which to compare an individual suspected to be suffering from 
AMI.   
Although AMI has been linked to ACL and other major knee joint injuries, it has yet to 
be shown as a result of PT.  Some evidence does exist that PT can cause concentric quadriceps 
weakness in female fencers. 10  Though concentric weakness could signal that AMI is present, it 
alone is not a definitive sign.  As in ACL injury, CAR and associated testing must be done to 
determine if the muscular weakness is due to AMI and where this AMI may be originating from.  
Movement Assessment 
 
The Landing Error Scoring System (LESS) is a clinical movement assessment tool, 
which was designed to help identify individuals at risk for ACL injury, but can also be used to 
help assess neuromuscular control during functional movement.  The LESS requires participants 
to jump off of a 30cm high box onto a force plate set at 50% of the participant’s height from the 
front of the box while being recorded by video cameras in the frontal and sagittal planes (Figure 
1). 46  To complete the trial the patient must successfully perform the jump, landing, and second 
jump three times (Figure 2).   
 
 
 
 
 
Figure 1. 46 
Figure 2. 46 
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After the patient has been filmed a clinician reviews the videos and grades the 
participant.  There are 22 error types that the LESS grades that range from knee valgus at initial 
contact to joint stiffness. 46 A high score on the LESS correlates to poor biomechanical landing 
abilities.  A poor score greater than 5 is considered predictive of ACL injury. 47 The LESS has 
been shown to; 1) have good validity when compared to motion analysis, 2) have good interrater 
(ICC2,k – 0.84 and SEM – 0.71) and intrarater (ICC2,1 – 0.91 and SEM – 0.42) reliability, and 3) 
identify at risk individuals. 46,48 This makes the LESS a clinically applicable test in the fields of 
overall lower extremity injury including ACL research, rehabilitation, and prevention strategies, 
although the LESS has not been specifically studied in the PT population. 
Future Directions  
 
 The purpose of this study is to identify AMI and the mechanisms leading to poor neural 
control.  If this study identifies altered neuromuscular outcomes future research will seek to 
identify ways to target pathways that lead to AMI or poor neural control.  One potential 
treatment is cryotherapy, which is a common modality in the clinical setting that might have 
further application in the treatment of AMI.  29   A second possible clinical approach to treating 
AMI is through motor neuron treatments, like neuromuscular electrical stimulation 35,49,50.  This 
is thought to work is by directly stimulating the affected motor neurons, causing a contraction to 
occur in inhibited muscle fibers. 31  A third clinical approach to treating AMI is through 
addressing the PT itself by using eccentrics to load the tendon 51-53 
Conclusion 
  
Patella tendinopthy is common, especially in athletes that participate in jumping sports. 
In athletes with PT, the physical and mechanical properties of pathological tendon differ from 
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normal.  The changes in tendon properties, which are evident in PT, have been shown to 
decrease concentric quadriceps strength. Decreases in quadriceps strength have also been 
evaluated in participants with ACL injury and in those with OA.  A component of the quadriceps 
strength impairment in both of these conditions is related to diminished neuromuscular control. 
Alterations in neuromuscular control after joint injury is often referred to as AMI.  CAR is one of 
the primary methods used to assess the magnitude of AMI but does not identify the pathways 
underlying the deficit.  To help identify exactly where the source of the AMI is originating from 
other measures must be utilized.  A combination of H-Reflex testing, to evaluate spinal cord 
influence, EMG, to determine alterations in dynamic muscular activity, and LESS score, a 
functional means of evaluating neuromuscular control were all used to make a complete picture 
of why AMI is present.  Quantifying the effects of quadriceps AMI induced by PT have not been 
extensively investigated and has not been quantified in terms of non-functional, CAR and H-
Reflex, and functional, EMG and LESS score, measures. Therefore, the purpose of this 
investigation is to quantify AMI that is potentially present as a result of PT using the CAR, and 
then to identify the pathways that are leading to the AMI using H-Relex, EMG, and LESS score.   
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Chapter II: Introduction 
 
Patellar tendinopathy (PT) is a degeneration of the patellar tendon that can impair athletic 
performance, quality of life, and neuromuscular control that may lead to future injury. 1 PT is 
particularly prevalent in jumping sports, such as volleyball, where it can affect close to 50% of 
elite male athletes in the sport. 2 Untreated PT can become a source of painful physical activity 
participation that can influence musculature around the knee by causing generalized weakness. 3 
Consequently, nearly 33% of athletes that have chronic PT  take longer than six months to return 
to play. 4,5 
Muscle weakness resulting from joint damage is often referred to as arthrogenic muscle 
inhibition (AMI). 6,7 AMI is thought to be a mechanism of the body to protect a joint following 
injury and is commonly seen in the quadriceps muscle group after anterior cruciate ligament 
(ACL) injury. 8 Two pathways are known to influence AMI, central and peripheral, each varying 
in ways of inhibiting muscle activity. 6-10 Peripherally induced AMI has been shown to be present 
in both experimental and injury models in conjunction with persistent pain, which is possible in 
patients with PT. 11 Losses in quadriceps strength and altered cortical excitability have been 
documented in patients with PT, 3,12 but it is unknown if AMI might result from peripheral or 
spinal mechanisms specifically in patients with PT.  
AMI can be quantified in many ways, which includes measuring the central activation 
ratio (CAR) and Hoffman’s reflex (H-Reflex).  CAR identifies the presence of AMI, through 
detecting a drop in volitional muscle activation that results from either a decrease in motor 
neuron firing rate or the number of motor units being recruited 13, but cannot pinpoint the source 
of the dysfunction (ie. either central or peripheral).  While Hoffmann-Reflex (H-reflex) is the 
normalization of spinal cord reflexivity to maximal muscle response (H:M ratio) in order to 
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quantify peripherally originating AMI.  H-Reflex is a method of stimulating 1a afferent fibers in 
the muscle spindle and recording the electrical activity that occurs in the target muscle following 
stimulation 9.  Since the afferent fibers must travel through the spinal cord, any alteration in 
resultant electrical activity from what is considered normal is attributed to spinal cord influence.  
Electromyography (EMG) is used during testing of the H-Reflex to detect electrical 
stimulus that is leaving the spinal cord or can be used to support other measures by showing how 
a patient is engaging various muscles during physical activity.  This is accomplished through 
recording the electrical activity between two conduction points, commonly surface electrodes, 
which takes place during depolarization while a muscle is at work.  Alterations in the quality of 
muscular activation may also influence movement control during functional activities.  Certain 
movements during sport-specific tasks, such as a jump landing, have been associated with lower 
extremity musculoskeletal injury risk, and such, are important to understand.  The Landing Error 
Scoring System (LESS) was designed as a specific clinical movement assessment tool for the 
jump-landing task.  Together these measures allow for the quantification of AMI and the 
identification of possible spinal cord involvement, along with the ability to understand muscular 
activation throughout physical activity and the role this may play in altered mechanics during a 
jump landing.  
Thus, the purpose of this study was to evaluate the presence and origin of AMI in 
individuals suffering from PT using CAR, EMG, and H-Reflex along with clinically applicable 
measures, such as the LESS and subjective patient-oriented outcome scales. Our hypothesis is 
that arthrogenic muscle inhibition will be present in patients with PT, leading to a decrease in 
CAR, muscle activity, H:M ratio, and LESS score. 
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Chapter III: Methods 
Participants 
 12 males (n=6) and females (n=6) between the ages of 13-40, were recruited to 
participate in this research study. Six participants were self-reported as having PT, with 
symptomatic PT quantified as score of < 80 on the Victorian Institute of Sport Assessment - 
Patella (VISA-P). Exclusionary criteria for PT participants were a history of lower extremity 
surgery, any lower extremity injury in the previous six months (other than PT), or having a heart 
related condition. Six other participants served as healthy controls, scoring between a 95 and 100 
on the VISA-P.  To be included in the control group, participants needed to be both healthy and 
physically active at the time of the trial, with no previous history of lower extremity surgery, 
current knee pain or have a heart related condition.  Each participant in the PT group was gender-
matched to a control participant that most closely resembled him or her in height and mass.  All 
participants completed informed consent forms, which were approved by the University of 
Connecticut’s Institutional Review Board. 
Quadriceps Activation Testing 
 
 To quantify defects in volitional muscle activation and determine whether AMI was 
present, superimposed burst (SIB) testing 14 was performed on a Biodex dynamometer (System 4, 
Biodex Medical Systems, Inc, Shirley, NY). 15 Each participant was positioned in the Biodex so 
that his or her hips and knees were both flexed to 90 degrees and the torso was flexed to 90 
degrees. 7  Two 7x13cm self adhesive stimulating electrodes were placed on the participant’s 
thigh in space that had already been cleaned with isopropyl alcohol and was shaved free of hair.  
The superior electrode was placed over the vastus lateralis so that its medial border was in line 
with the anterior superior iliac spine at the level of the greater femoral trochanter.  The inferior 
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electrode was placed over the vastus medialis so that the lateral border aligned with the midpoint 
of the patella at a height of 1.5 inches above the superior pole of the patella.  
Once the participants were properly positioned, a series of three introductory practice trials 
were conducted.  For the practice trials the participants were instructed to extend their knee at 25, 
50, and 75% of their perceived maximal exertion.  At the same time as contraction, a stimulus of 
corresponding percentage of the maximal 150 volts was delivered to the participant’s quadriceps.  
A custom written program (LabVIEW Version 8.5; National Instruments Corporation, Austin, 
TX) delivered each stimulus as a 100ms train of 10 stimuli, at 100 pps, with a pulse duration of 
0.6ms, and a 0.01ms pulse delay 16.  After the introductory practice trials were complete the 
participant was instructed to complete three MVIC trials, or until the researcher determined that 
the participant was putting forth full effort, without any electrical stimulation.  Finally, three 
MVIC trials were completed along with electrical stimulation equal to 100% of the 150 volt 
maximum.  The participants were given visual feedback and verbal encouragement during each 
trial and a 60 second recovery session between each trial.  The entire procedure was then 
completed on the contralateral limb and the order of tested limbs was counterbalanced. The 
lowest of the three trials was used in data analysis.  A Grass S48 dual-output square-pulse 
stimulator and SIU8T isolation unit (Grass-Telefactor, West Warwick, RI) was used in the 
application of the superimposed bursts.  
Additionally, to quantify alterations in muscle activity prior to the burst, surface 
electromyographical electrodes (EMG, Desktop DTS, myoMuscle, Scottsdale AZ, USA) were 
secured over the muscle bellies of the vastus lateralis and medialis according to the technique 
described by Delagi et al. 17 and were sampled (1500Hz) and synchronized (Analog Input 
System, Noraxon Inc. Scottsdale AZ, USA) with the torque from the dynamometer. EMG data 
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data was collected from the onset of muscle contraction was defined at 7.5Nm 18 to assure that 
baseline movement had been exceeded until 100 msec prior to the superimposed burst.  
Hoffmann reflex testing 
 
To measure difference in spinal-reflexive excitability H-Reflex testing 9 was performed 
using an electromyography (EMG) and stimulation unit (STM100A, BIOPAC Systems, Inc.).  
Participants were positioned supine on a portable treatment table with their arms placed at their 
side, head resting in neutral on a pillow, and knees bent in about 10-15 degrees of flexion and 
supported by a half bolster.  Two 10mm, pre-gelled Ag-AgCl EMG electrodes (EL503, BIOPAC 
Systems, Inc.) were placed 1.75 cm apart in cleaned and shaven sites over the medial vastus 
medialis muscle belly.  EMG signals were band-pass filtered from 10 to 50 Hz and collected at 
1024HZ with a common-mode-rejection ratio of 110 dB.  A 2mm shielded disc stimulating 
electrode (EL2524S, BIOPAC Systems Inc) was positioned over the femoral nerve and secured 
with hypoallergenic tape and a 7x13cm self adhesive electrode was positioned over the 
hamstring and used as a dispersive electrode. A 1ms square wave stimulus was produced using 
the BIOPAC stimulator module and a 200 volt maximum stimulus adaptor (STMISOC, BIOPAC 
Systems Inc.) and was delivered to the femoral nerve.   
The participants maintained constant head, eye, and hand position during testing by 
focusing on a small circle on the ceiling.  Once each participant was settled, the stimulus was 
applied in 2 volt increments until a maximal H-Reflex was obtained.  After the first maximal 
reflex was obtained, three more were elicited using the same voltage setting.  Next, the voltage 
was increased until a maximal muscle response was obtained, and followed by three concurrent 
trials of eliciting maximal muscle response.  The average of the three maximal H-Reflexes were 
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normalized to the average of the three maximal muscle responses for analysis. This procedure 
was then repeated for the contralateral limb and the order of tested limbs was counterbalanced.  
Sonographic Assessment 
 
  Sonographic measurements were taken using an ultrasound unit (Philips, 12-5L linear 
transducer).  Participants were supine with the knee flexed between 80-90 degrees in order to 
relax the quadriceps muscles. 19  A clinician trained in the use of US for studying patellar tendon 
abnormalities obtained both longitudinal and transverse images of the patellar tendon.  The 
abnormalities studied were tendon thickening, hypochoic regions, and areas of 
neovascularization. Tendons with one or more abnormality were considered to be objectively 
defined PT.  Abnormality was used to break the PT group into two subgroups, where participants 
with tendon abnormality were defined as objective PT and subjects without abnormality were 
defined as subjective PT.  These images were transferred to an external had drive so that could 
be examined later for structural abnormalities.  The US examiner was blinded to participant 
groupings. 
Movement Assessment  
 
 Following the CAR trials, participants completed at least one familiarization trial 
followed by three trials of a standardized jump-landing task.  Participants were required to jump 
forward a distance of half their height from a 30cm high box and land with each foot on a 
separate non-conductive force plate (model 4060-NC; Bertec Corporation, Columbus, OH), 
which sampled landing data at 1500 Hz. Immediately following landing, participants jumped for 
maximal height in one fluid motion. Trials were repeated if the participants’ feet did not leave 
the box at the same time, the participants did not immediately jump after landing, or if they 
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jumped too far or too short.  Each test was recorded by two video cameras, one in the sagittal 
plane and one in the frontal plane. A single rater, blinded to group, evaluated the trials using the 
Landing Error Scoring System (LESS), which is a valid and reliable clinical movement screening 
tool. 20 The EMG system and electrode placement was not changed between CAR and jump 
landing trials, but the system was synced with both force plates so that muscle activity could be 
aligned in time during jump landing.    
Data Reduction and Analyses 
 
EMG data collected during isokinetic testing and jump landings were analyzed to 
determine if differences in the average muscle activity during these tasks existed in participants 
with PT. To do this, the raw EMG data were subsequently processed within the Noraxon 
software (MR3, myoMuscle, Scottsdale Arizona, USA). Specifically, raw EMG signals were 
band-pass filtered 6 to 1,000 Hz, rectified and then processed using a root-mean-square 
algorithm with a 50-millisecond moving window. EMG collected during the isokinetic and jump 
landing tasks were then normalized to the peak muscle activity that was recorded from either 
task. Using this normalization technique, all normalized root-mean-square data were at or below 
100% of muscle activity. 21 EMG data for the isokinetic testing were analyzed between the onset 
of muscle contraction to 100msec prior to the burst. EMG during the landing task was then 
analyzed during two phases of activity: pre-loading (100 milliseconds prior to ground contact) 
and loading (ground contract to take-off) 22.  Ground contact was defined as a force exceeding 10 
Nm, while take off was defined as a force below 10 Nm 22. 
 Descriptive statistics are presented as means +/- SD.  Statistical analyses were performed 
using SPSS (Version 22). Independent t-tests were used to assess group differences between PT 
and control participants for CAR, H:M ratio, LESS score, and average muscle amplitude during 
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both CAR, and the pre-loading and loading phases of jump landing.  Assumptions of equal 
variance and normal distribution were ensured with no abnormalities.  Descriptive statistics were 
used to discuss differences in sonographic assessment.  Significance was set a priori at an alpha 
level of < 0.05 and 95% confidence interval (CI), reported as lower bound (LB) and upper bound 
(UB), around the mean differences was calculated.  Each dependent variable was considered 
independent constructs thus Family Wise Error was not accounted in this analysis. 
 
Chapter IV: Results 
 
Demographics 
 
 No significant difference in age, gender, or mass existed between groups (see table 1, 
p>0.05). The PT group was found to be significantly taller than the healthy group (see table 1, 
p<0.05). 
 
 
 
 
 
 
 
 
 
 
 
Table 1: Group Demographics (Mean ± SD) 
Demographic Group n Mean 95% CI: LB 95% CI: UB 
Age (years) 
PT 6 20.83±0.98 
-5.59 1.59 
Healthy 6 22.83±3.82 
Gender 
PT 6 0.50±0.55 
-0.71 0.71 
Healthy 6 0.50±0.55 
Height (cm) 
PT 6 177.80±6.81* 
0.32 14.87 
Healthy 6 170.20±4.18 
Weight (kg) 
PT 6 74.00±8.67 
-7.21 15.87 
Healthy 6 69.67±9.27 
*Indicates significance (p<0.05) 
95% CI indicates difference between groups 
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VISA-P 
 
 All subjects in the PT group scored under an 80 on the VISA-P (62.67 ± 17.38), while all 
healthy subjects scored at or above a 99 (99.83 ± .41).  Both groups met the criteria defined by 
the VISA-P for their respective groups. 
US 
 
 Two of the six subjects in the PT group were classified as having PT through diagnostic 
imaging, with one of the 2 being diagnosed with bilateral tendon involevment.  The remaining 
four subjects had no visible PT present in the affected limb (see Figure 1).  All six of the healthy 
subjects were shown to have no visual evidence of PT in either limb.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Demonstrates the tendons 
from the involved limbs for the PT 
group.  A, C, D, and E refer to 
participants with subjectively 
reported PT, normal tendons 
(Denoted by arrows). Tendons B 
and F refer to diagnostic (objective) 
PT as shown by their increased 
width and areas of hypochoic 
legions (Denoted by arrows).   
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CAR 
 
 I observed a significant deficit in volitional muscle activation in the involved limb in 
patients with patellar tendinopathy as compared to the healthy group (F = 10.279; p = .04; Cohen 
d = 1.37; 95% CI: -6.60, -0.21, see table 2).  
Table 2. Central Activation Ratio (Mean ± SD) 
Limb Group n Mean 95% CI: LB 95% CI: UB 
Involved  
PT 6 95.13±3.46* 
-6.60 -0.21 
Healthy 6 98.54±0.60 
 Non-Involved 
PT 6 96.97±2.21 
-3.26 1.25 
Healthy 6 97.98±1.12 
*Indicates significance (p<0.05) 
95% CI indicates difference between groups 
 
Muscle Activity 
 
 No significant differences were found between the PT and healthy groups for vastus 
medialis or vastus lateralis activity during SIB, pre-loading, or loading (see tables 3-5, p>0.05). 
Table 3. EMG: Percent maximal activation during CAR  (Mean ± SD) 
Limb: Muscle Group n Mean 95% CI: LB 95% CI: UB 
Involved: Vastus Lateralis 
PT 6 15.67±19.89 
-27.85 14.37 
Healthy 6 22.36±11.97 
 Involved: Vastus Medialis 
PT 6 23.32±15.14 
-15.92 20.26 
Healthy 6 21.15±12.89 
Non-Involved: Vastus 
Lateralis 
PT 6 20.43±20.78 
-19.09 26.66 
Healthy 6 16.65±14.15 
Non-Involved: Vastus 
Medialis 
PT 6 35.15±29.62 
-6.06 49.45 
Healthy 6 13.46±7.32 
*Indicates significance (p<0.05) 
95% CI indicates difference between groups 
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Spinal Reflexive 
 
 No significant difference was found between the PT and healthy groups in H:M ratio (F = 
2.665; p = 0.82; 95% CI: -0.20, 0.25, see table 6).  
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 4. EMG: Percent maximal activation during pre-loading  
(Mean ± SD) 
Limb: Muscle Group n Mean 95% CI:LB 95% CI: UB 
Involved: Vastus Lateralis 
PT 6 7.93±5.34 
-7.53 4.49 
Healthy 6 9.45±3.90 
Involved: Vastus Medialis 
PT 6 9.06±3.29 
-5.25 5.34 
Healthy 6 9.01±4.80 
Non-Involved: Vastus 
Lateralis 
PT 6 8.56±4.24 
-20.81 11.13 
Healthy 6 13.40±17.03 
Non-Involved: Vastus 
Lateralis 
PT 6 9.46±4.56 
-8.03 6.53 
Healthy 6 10.21±6.57 
*Indicates significance (p<0.05) 
95% CI indicates difference between groups 
Table 5. EMG: Percent maximal activation during loading (Mean ± SD) 
Limb: Muscle Group n Mean 95% CI: LB 95% CI: UB 
Involved: Vastus Lateralis 
PT 6 29.23±9.83 
-28.51 2.22 
Healthy 6 42.37±14.05 
Involved: Vastus Medialis 
PT 6 43.17±6.79 
-8.09 24.56 
Healthy 6 34.93±16.61 
Non-Involved: Vastus 
Lateralis 
PT 6 31.56±11.13 
-8.99 19.64 
Healthy 6 26.23±11.13 
Non-Involved: Vastus 
Lateralis 
PT 6 38.00±15.33 
-9.80 27.87 
Healthy 6 28.97±13.92 
*Indicates significance (p<0.05) 
95% CI indicates difference between groups 
Table 6. H:M Ratio (Mean ± SD) 
Limb Group n Mean 95% CI: LB 95% CI: UB 
Involved 
PT 6 0.22±0.23 
-.20 .25 
Healthy 6 0.20±.09 
Non-Involved 
PT 6 0.30±.22 
-.56 .22 
Healthy 4 0.47±.32 
*Indicates significance (p<0.05) 
95% CI indicates difference between groups 
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LESS Score 
 
 No significant difference was found between the PT and healthy groups in average LESS 
score (F = .260; p = .66; 95% CI: -1.51, 2.29, see table 7).   
Table 7. Average LESS Score (Mean ± SD) 
LESS Score Group n Mean 95% CI: LB 95% CI: UB 
Average 
PT 6 4.94±1.64 
-1.51 2.29 
Healthy 6 4.56±1.29 
*Indicates significance (p<0.05) 
95% CI indicates difference between groups 
 
 
Sub-Group Analysis 
To more accurately report CAR, H:M, muscle activity, and LESS the PT group was 
divided into two sub-groups in addition to the PT group as a whole.  First, a Subjective group, 
diagnosed with PT based off subjective questionnaires, and second, an Objective group, 
diagnosed with PT based off a combination of subjective reports and positive identification of 
tendon abnormality via US, groups.  The purpose of this division was to identify the differences 
that appeared between subjects with and without tendon abnormality and to demonstrate varying 
levels of severity within the PT group.  All sub-group analyses were done descriptively due to 
the small sample sizes. 
Sub-Group CAR 
The objective PT group demonstrated a lower CAR than both the subjective PT and 
healthy groups (see table 8).  
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Table 8. Central Activation Ratio with sub-groups (Mean 
± SD) 
Limb Group n Mean 
Involved  
Objective PT 2 93.66±0.82 
Subjective PT 4 99.00±0.62 
Healthy 6 98.54±0.60 
Non-Involved 
Objective PT 2 94.91±2.76 
Subjective PT 4 98.00±1.15 
Healthy 6 97.98±1.12 
 
Sub-Group EMG 
The objective PT group exhibited lower vastus lateralis and medialis activation during 
SIB, pre-loading, and loading trials in both the involved and non-involved limbs when compared 
to both the subjective PT and healthy groups (see tables 9-11) 
 
Table 9. EMG: Percent maximal activation during CAR 
with sub-groups (Mean ± SD) 
Limb: Muscle Group n Mean 
Vastus Lateralis: Involved 
Objective PT 2 4.57±2.84 
Subjective PT 4 21.14±23.11 
Healthy 6 22.36±11.97 
 Vastus Medialis: Involved 
Objective PT 2 13.03±4.24 
Subjective PT 4 28.47±16.43 
Healthy 6 21.15±12.89 
Vastus Lateralis:Non- Involved 
Objective PT 2 8.44±7.44 
Subjective PT 4 26.42±23.62 
Healthy 6 16.65±14.15 
Vastus Medialis: Non-Involved 
Objective PT 2 7.46±1.13 
Subjective PT 4 49.00±26.36 
Healthy 6 13.46±7.32 
 
 
 
 
 37 
Table 10. EMG: Percent maximal activation during pre-
loading with sub-groups (Mean ± SD) 
Limb: Muscle Group n Mean 
Vastus Lateralis: Involved 
Objective PT 2 2.95±1.97 
Subjective PT 4 10.43±4.61 
Healthy 6 9.45±3.90 
Vastus Medialis: Involved 
Objective PT 2 6.05±2.45 
Subjective PT 4 10.56±2.64 
Healthy 6 9.01±4.80 
Vastus Lateralis: Non-Involved 
Objective PT 2 6.15±4.91 
Subjective PT 4 9.77±4.02 
Healthy 6 13.40±17.03 
Vastus Lateralis: Non-Involved 
Objective PT 2 6.64±2.08 
Subjective PT 4 10.88±5.03 
Healthy 6 10.21±6.57 
 
Table 11. EMG: Percent maximal activation during 
loading with sub-groups (Mean ± SD) 
Limb: Muscle Group n Mean 
Vastus Lateralis: Involved 
Objective PT 2 18.70±2.92 
Subjective PT 4 34.49±5.75 
Healthy 6 42.37±14.05 
Vastus Medialis: Involved 
Objective PT 2 38.62±4.69 
Subjective PT 4 45.44±6.98 
Healthy 6 34.93±16.61 
Vastus Lateralis: Non-Involved 
Objective PT 2 20.83±0.189 
Subjective PT 4 36.92±9.56 
Healthy 6 26.23±11.13 
Vastus Lateralis: Non-Involved 
Objective PT 2 22.47±2.03 
Subjective PT 4 45.77±12.21 
Healthy 6 28.97±13.92 
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Sub-Group Spinal Reflexive 
The objective PT group was found to demonstrate a lower H:M ratio in both the involved 
and non-involved limbs when compared to both the subjective PT and healthy groups (see table 
11).   
Table 12. H:M Ratio with sub-groups (Mean ± SD) 
Limb Group n Mean 
Involved 
Objective PT 2 0.07±0.05 
Subjective PT 4 0.29±0.26 
Healthy 6 0.20±0.09 
Non-Involved 
Objective PT 2 0.14±0.04 
Subjective PT 4 0.38±0.24 
Healthy 4 0.47±0.32 
 
Sub-Group LESS Score 
The objective PT group were found to higher LESS scores than the subjective PT and 
healthy groups (see table 13).  
Table 13. Average LESS Score with sub-groups               
(Mean ± SD) 
LESS Score Group n Mean 
Average 
Objective PT 2 6.67±0.47 
Subjective PT 4 4.08±1.20 
Healthy 6 4.56±1.29 
 
Chapter V: Discussion 
 
 This research study was the first to quantify AMI originating from peripheral sources in 
the PT population.  Prior research has evaluated cortically driven neuromuscular changes in 
chronic PT cases 12 and deficits in strength exhibited by PT subjects 3 but neither previous study 
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defined the amount of quadriceps inhibition present in the condition.  The current study found 
evidence of the presence of AMI resulting from peripheral mechanisms at the spinal cord level in 
subjects with PT.  Further, it was found that those subjects demonstrating objective PT, as 
confirmed by US, also demonstrated alterations in muscle activity and movement control, 
possibly resulting from the increased tendon abnormality.  
Identifying Patellar Tendinopathy 
 
 The VISA-P is a means of determining the severity of PT based on subjective patient 
reports of pain and dysfunction.  From the results of this study, it is reasonable to suggest that the 
VISA-P can also detect neuromuscular dysfunction since the PT group demonstrated neural 
alterations, but further investigation would be needed.   All subjects met their group’s VISA-P 
inclusion criteria and were placed in the appropriate group.  Although, there was variability 
within the PT group as scores ranged from 30-79 respectively.  This wide range demonstrated the 
need for objective testing of tendon injury severity in addition to solely subjective reports of 
pain.  
As the abnormality and pain do not always occur together it was expected that there 
would be discrepancies between subjective and objective reporting, which has been previously 
demonstrated. 19,23  Only two of the six subjects in the PT group had tendon abnormalities upon 
investigation by diagnostic US imaging (Fig. 1), while the remaining four PT participants did not 
show any evidence of PT through imaging.  This is important clinically because individually 
both subjective and objective reporting measures can be used to detect PT, but combining both 
measures may be the most cost effective and efficient method.   
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Quantifying Arthogenic Muscle Inhibition 
 
 This study was the first to quantify AMI in PT patients using both CAR and H-Reflex.  
Together these techniques allow for the identification of altered volitional muscle activation, 
which is originating either from a decrease in motor neuron firing rate or the number of available 
motor units, and an evaluation of the quality of afferent signaling from the muscle spindle 
reaching the spinal cord.  This is important because simply identifying the presence of AMI does 
not describe the underlying source or mechanism.  When looking at CAR, the PT group 
demonstrated a decrease in volitional muscle activation as compared to the healthy group (Table 
2).  In particular, those individuals with tendon abnormalities on diagnostic imaging showed an 
even larger decrease in volitional muscle activation when compared to both the remainder of the 
PT group and healthy individuals (Table 8).  These differences in CAR within the PT group may 
have been caused by variations in the origin of AMI.  Based on the data it appeared that the 
subjective PT group may have been suffering from centrally driven AMI due to the decrease in 
volitional muscle activation even with a lack of detectable peripheral mechanisms.  Conversely, 
the objective group may have been suffering from a combination of peripheral and central 
mechanisms of AMI due to the chronic nature of their injuries.  This thinking is derived from 
previous literature showing chronic PT can cause cortical level changes 12,and my data that 
demonstrated a decrease in H:M ratio.  The observed decrease in volitional muscle activation, for 
either group, did not reach levels seen in more serious injuries, like ACL rupture, which was 
expected.  PT does not exhibit similar levels of joint damage, swelling, or pain as are seen in 
major ligament rupture.  A second reason could be that even the two subjects with tendon 
abnormality and a decreased CAR were still fully functional in sport.  
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Unlike CAR, no difference in H:M appeared between the PT group and healthy 
individuals (Table 6).  Although, once the PT group was through US the objective PT group 
demonstrated a lower H:M in both the involved and uninvolved limbs (Table 12).  These data 
suggest that the spinal cord is modifying afferent signaling from the periphery and could be a 
result of dysfunction in the gamma loop, Renshaw cells or type 1a. Spinally induced AMI is not 
caused by peripheral mechanisms, such as pain or effusion, which can be modulated by reducing 
the amount of afferent signaling.  In these peripheral models AMI can be reduced by simply 
decreasing the amount of joint effusion or by reducing the amount of pain felt.  This could be 
why there was a difference between the two PT sub-groups in regards to H:M.  The objective 
group was likely suffering from peripherally driven AMI due to altered afferent feedback 
resulting from tendon abnormality, while in both sub-groups centrally driven AMI resulting from 
their chronic PT was likely caused a reduction in CAR as compared to the healthy group.   
Functional Impact 
 
 As was previously reported, the results of this study show that PT can lead to AMI that is 
likely originating from peripheral and central mechanisms, but neither CAR nor H-Reflex is a 
measure of functionality during physical activity.  It is important to understand how AMI in the 
PT population translates into alterations in muscular activity and neuromuscular control during 
functional activities.   
Neuromuscular control during functional activities, such as a jump landing, is important 
to evaluate due to its association with injury risk. 24  Previous work has linked AMI to functional 
deficits in neuromuscular control that may explain the elevated risk of subsequent injury in 
individuals after knee joint injury, but this work has been largely isolated to patients after ACL 
injury. Palmeiri-Smith et al 25 found that patients with AMI generally demonstrate altered 
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kinematics, but this research has not been thoroughly reproduced in the PT population.  This is 
one of the first studies to score jump landings in the PT population.  While there were no 
statistically significant differences between groups in LESS scores (Table 7) the objective PT 
group demonstrated higher LESS scores than either other group (Table 13).  Furthermore, the 
mean scores for the objective PT group were above six, which has been shown to be predictive 
of ACL injury in a youth population 26 and may suggest greater neuromuscular compromise in 
these individuals.  These findings support the critical need for clinicians to evaluate movement 
control in patients recovering from knee joint injuries. 
One possibility for the objective PT group’s increased scores was altered muscular 
activity prior to and during landing.  The objective PT group had generalized decreased activity 
in the vastus medialis and lateralis that was not seen in the either the subjective or healthy 
control groups and a lower percent max activation during the loading phase of jump landing in 
the vastus lateralis.  Conversely, the PT group demonstrated activation that was greater than or 
equal to healthy individuals in all other trials (Table 5), but these data are not meant to suggest 
that individuals with PT demonstrate normal levels of quadriceps activation.  Once the PT group 
was separated into subgroups it became apparent that those with diagnostically identified tendon 
abnormality demonstrated decreased muscle activation during the SIB trials (Table 9) and the 
pre-loading (Table 10) and loading phases (Table 11) of jump landing for both the vastus 
lateralis and medialis muscle groups.  This suggests that the objective PT group might have been 
compensating with higher activation in a different muscle group that was not quantified in this 
study through the use of EMG, or the group had an overall decrease in quadriceps muscle 
activation, even on muscles not analyzed.  The latter is supported through the objective PT 
group’s decrease in CAR and increased LESS score.  This could be evidence that AMI 
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originating from central mechanisms can have an effect on muscular activity that is significant 
enough to alter landing kinematics.  Further investigation is warranted into the source of this 
decreased activity and whether PT induced AMI is associated with injury risk. Clinically, 
landing mechanics may be an area of observation that is added to PT evaluations. 
Limitations 
 
Overall, the limitations of this study were disparity between levels of dysfunction in the 
PT group and its small sample size.  One possibility that could explain why not all subjects 
demonstrated neuromuscular dysfunction could be due to the disparities in the origin of the PT. 
Peripheral mechanisms were shown to be affected in the two objective PT subjects through their 
decreased H:M.  Other subjects were not as acutely injured, which may explain why they did not 
have alterations in H-Reflex outcomes.  For these subjects cortical measures may have been 
more appropriate to assess neuromuscular alterations.  Cortical alterations have been 
demonstrated in various ACL injury models 27,28 and previous literature suggests that chronic PT 
can cause changes in cortical pathways, which caused neuromuscular dysfunction. 12  Further, 
research into long term injury outcomes in subjects with previous ACL injury has shown that 
these cortical alterations can evolve over time as a response to injury. 9 A larger sample of more 
severely injured participants would be needed to accurately assess the amount of dysfunction 
potentially caused by PT.  
Future Direction 
 
 Future research needs to evaluate the effects of PT on neuromuscular function in a larger 
sample consisting of acute and chronic PT of varying injury level.  Further, this research should 
aim to evaluate both peripheral and cortical pathways over time to see how the course of the 
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injury may cause changes in neuromuscular outcomes.  Finally, a protocol that includes a 
treatment program would be necessary to observe how both peripheral and cortical pathways 
evolve as tendon health improves.  This rehabilitation plan should include ways to treat the 
various underlying causes of AMI present in PT cases.  
Conclusions 
 
 PT can lead to neuromuscular dysfunction in the quadriceps during varying levels of 
activity.  Individuals with PT exhibit quadriceps AMI that seems to partially stem from 
peripheral inhibition at the spinal cord level.  These individuals with objectively quantified PT 
also demonstrate lower muscle activity during voluntary isometric contractions and the phases of 
jump landing, which may be the source of their increased LESS scores.  The topic of quadriceps 
AMI caused by PT is novel and future research is needed to account for the small sample size 
and relatively healthy PT population.  An investigation into PT detrimental enough to cause a 
cessation of athletic participation is needed to determine to what extent PT can influence 
neuromuscular dysfunction and the origin of AMI in this population.  Clinically, this research 
presents data that subjects with PT could present with AMI of varying levels corresponding with 
the amount of tendon abnormality.  Rehabilitation practices should focus on not only the tendon 
itself but also the quadriceps musculature, which are commonly used to combat AMI seen after 
ligamentous injury. 7,29-31  
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